Study Assessing QBS72S For Treating Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Brain Metastases
Related studies linked through entity extraction aliases.
HyperArc Registry Study
- Status
- COMPLETED
- Phase
- N/A
Preop fSRS for Resectable Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
- Status
- WITHDRAWN
- Phase
- PHASE2
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- Status
- TERMINATED
- Phase
- PHASE1
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
- Status
- UNKNOWN
- Phase
- PHASE2
BRIANSTORM - Early Identification of Patients With Brain Metastases
- Status
- UNKNOWN
- Phase
- N/A
Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife
- Status
- UNKNOWN
- Phase
- PHASE2
Hypofractionated Versus Single Fraction Stereotactic Adjuvant Radiotherapy to the Resection Cavity of Brain Metastases
- Status
- UNKNOWN
- Phase
- NA
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of the CONVIVO System
- Status
- RECRUITING
- Phase
- NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- Status
- RECRUITING
- Phase
- NA
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
- Status
- RECRUITING
- Phase
- NA
NTS-WBRT in Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1